Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E21.29 EPS (ttm)2.66 Insider Own0.10% Shs Outstand1.67B Perf Week3.61%
Market Cap94.68B Forward P/E18.29 EPS next Y3.09 Insider Trans-1.27% Shs Float1.67B Perf Month20.80%
Income4.46B PEG1.47 EPS next Q0.75 Inst Own71.50% Short Float0.81% Perf Quarter0.32%
Sales19.43B P/S4.87 EPS this Y184.60% Inst Trans0.56% Short Ratio1.07 Perf Half Y-2.44%
Book/sh9.66 P/B5.86 EPS next Y9.92% ROA13.50% Target Price55.37 Perf Year-6.87%
Cash/sh3.79 P/C14.91 EPS next 5Y14.47% ROE29.20% 52W Range46.01 - 76.09 Perf YTD-2.58%
Dividend1.56 P/FCF- EPS past 5Y4.20% ROI20.00% 52W High-25.66% Beta1.07
Dividend %2.76% Quick Ratio1.40 Sales past 5Y-1.80% Gross Margin74.60% 52W Low22.93% ATR1.42
Employees25000 Current Ratio1.60 Sales Q/Q22.30% Oper. Margin30.80% RSI (14)64.79 Volatility2.71% 2.26%
OptionableYes Debt/Eq0.41 EPS Q/Q550.30% Profit Margin22.90% Rel Volume0.90 Prev Close56.44
ShortableYes LT Debt/Eq0.35 EarningsJan 26 BMO Payout57.00% Avg Volume12.53M Price56.56
Recom2.40 SMA208.15% SMA503.03% SMA200-5.75% Volume11,284,928 Change0.21%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Feb-27-17 05:05PM  BMY Is Expected to See a Small Rise in Its 2017 Net Profit Margin
04:34PM  Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team
03:35PM  Bristol-Myers Squibb Expects Modest Revenue Growth in 2017
02:30PM  Cramer: Money's Being Thrown at Almost Everything in the Market
01:54PM  Analysts Recommendations for Bristol-Myers Squibb in 2017
01:22PM  Why You Shouldn't Look Down On Your Depressed Colleagues at Forbes
11:46AM  Billionaire Julian Robertson Bets Big on Technology Sector With These Stocks at Insider Monkey
09:54AM  [$$] VC Profile: OrbiMed Funds Novel Attacks on Cancer at The Wall Street Journal
09:30AM  Bristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global Health Care Conference Business Wire
09:25AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:06AM  Eli Lilly & Co.s Oncology Franchise
07:38AM  Pfizers Innovative Health and Essential Health in 4Q16
06:59AM  Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma Business Wire
06:59AM  Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre Business Wire
04:09AM  Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?
01:00AM  IBM, Apple, Amazon: Doug Kass' Views
Feb-26-17 11:56AM  Billionaire Carl Icahn Is Reportedly Buying Bristol-Myers Squibb Stock -- Should You? at Motley Fool
Feb-24-17 07:01PM  Cramer: I'll Give You the Key to the Rally
01:04PM  BRISTOL MYERS SQUIBB CO Financials
07:27AM  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
Feb-23-17 05:59PM  Final Trade: ORCL, AN & more
05:15PM  Eli Lilly & Co.s Revenues in 4Q16
04:15PM  Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals
02:25PM  Bristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest at Insider Monkey
10:10AM  Company News for February 23, 2017
09:24AM  Januvia and Janumet: Merck & Co.s Blockbuster Diabetes Products
06:00AM  Why Do Stocks' Fair Value Estimates Change? at Morningstar
Feb-22-17 07:34PM  You'd be a fool to bet against the market now: Cramer
07:01PM  Cramer: Buyers for Bristol-Myers Are Few and Far Between
06:31PM  Cramer spells out why you would be a fool to bet against ...
06:21PM  Who Could Buy Bristol-Myers Squibb? at Motley Fool
06:00PM  Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes Business Wire
05:13PM  Bristol Myers' Future Unsure as Carl Icahn Takes Stake
03:10PM  Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
03:01PM  S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'
01:30PM  Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease at Motley Fool
01:04PM  US STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high
12:50PM  Carl Icahn Takes Stake in Bristol-Myers Squibb at MarketWatch
12:33PM  This bullish stock signal has never been wrong and its about to flash for 2017 at MarketWatch
12:29PM  Carl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target
11:44AM  US STOCKS-Wall St slightly lower ahead of Fed minutes
10:57AM  Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes
10:33AM  Takeover speculation surrounds Bristol-Myers Squibb
10:00AM  DISH tunes in solid profits, Toll builds on earnings & Carl Icahn eyes Bristol-Myers Squibb
09:30AM  Bristol-Myers Squibb Company -- Moody's rates Bristol's notes A2; negative outlook at Moody's
09:08AM  Merck & Co.s Segment-Wise Revenues for 4Q16
08:55AM  Stock Futures Waver as Wall Street Awaits Clarity From the Fed
08:39AM  Carl Icahn's Next Target: Bristol-Myers Squibb at Forbes
08:07AM  Fed minutes in focus
08:03AM  Stock market set to lose grip on records as Fed minutes loom at MarketWatch
07:32AM  Is Carl Icahn Targeting Bristol-Myers Squibb for a Takeover? at Investopedia
05:36AM  U.S. stocks on pause after record rally, with Fed minutes ahead
02:07AM  Factor Xa's Win Billions of Dollars in Sales From Warfarin at Motley Fool
01:44AM  PRESS DIGEST - Wall Street Journal - Feb 22 Reuters
12:42AM  [$$] Carl Icahn Takes Stake in Bristol-Myers Squibb at The Wall Street Journal
Feb-21-17 07:49PM  [$$] Carl Icahn Takes Stake in Bristol-Myers at The Wall Street Journal
06:59PM  Can Carl Icahn Save Bristol Myers Squibb?
05:10PM  Carl Icahn Reportedly Invests In Potential Takeout Target Bristol-Myers
04:56PM  Icahn buys Bristol-Myers shares, adding to activist pressure
04:48PM  Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
04:11PM  Bristol-Myers Rises After Report That Carl Icahn Owns Stake
04:00PM  Carl Icahn takes stake in Bristol Myers: WSJ
03:51PM  Carl Icahn has reportedly taken a stake in Bristol-Myers and its shares are jumping
03:46PM  Icahn takes stake in Bristol-Myers: DJ
03:45PM  Icahn Purchases Stake in Bristol-Myers
02:30PM  Bristol-Myers Adds Three New Directors
02:13PM  Bristol-Myers Buys Back Shares, Shuffles Board
11:10AM  Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment at Insider Monkey
08:18AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
07:50AM  Bristol-Myers adds three directors in deal with Jana Partners
07:36AM  How Amgens Kyprolis Is Positioned in Second-Line Multiple Myeloma Segment
07:22AM  Bristol-Myers announces $2 bln accelerated share buyback; adds former Bausch & Lomb CFO, others to board at MarketWatch
06:59AM  Bristol-Myers Squibb Appoints Three New Independent Directors Business Wire
03:00AM  First Comprehensive Pediatric Hematology-Oncology Initiative Launched in Africa Business Wire
Feb-17-17 07:41PM  Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market
07:34PM  These Are The First Immune-System Cancer Drugs OK'd By FDA
Feb-16-17 12:36PM  Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook
12:06PM  David Tepper Invests Heavily in Pharma in 4th Quarter
11:41AM  How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners at Motley Fool
Feb-15-17 07:34PM  3 Stocks We're Watching in the First Quarter at Motley Fool
12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at Barrons.com
11:19AM  Merck: There's Only One Way to Outperform Now at Barrons.com
10:41AM  Here Are The Major Moves Made By Bridgewater Associates Going Into 2017 at Insider Monkey
09:30AM  Markets Continue to Hit Record Highs: Today's Research Reports on Stocks to Watch Bristol-Myers Squibb and Himax Technologies Accesswire
Feb-14-17 03:33PM  Bristol-Myers Squibb: Takeover Target? at Barrons.com
Feb-13-17 05:17PM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
04:12PM  Tampa business leaders speak out on incentives, tourism marketing during Gov. Scott's visit (Video) at bizjournals.com
02:31PM  Bristol-Myers Squibb Company -- Moody's revises Bristol's outlook to negative; affirms A2/Prime-1 at Moody's
12:43PM  Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company
Feb-10-17 08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-09-17 06:44PM  [$$] Bristol-Myers Squibb Stock in Bargain Bin at Barrons.com
11:00AM  [$$] Brakes on the pathway to treating cancer at Financial Times
Feb-08-17 10:54AM  Bristol-Myers Squibb to Take Part in Leerink 6th Annual Global Health Care Conference Business Wire
10:17AM  Gilead Sciences & Bristol Myers: Two Wrongs Make a Right? at Barrons.com
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
08:05AM  These 2 Factors Sent Bristol-Myers Squibb Co. Tumbling by 16% in January at Motley Fool
07:47AM  Bristol-Myers Leukemia Drug Fails Mid-Stage Study at Investopedia
Feb-03-17 05:28PM  Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
04:29PM  AstraZeneca Shrugs Off Bristol-Myers' Setback; Crushes Q4 Views
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. The company has collaboration with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM